The heterocyclic substituted pyridine derivative (±)-2-(-3-pyridinyl)- 1-azabicyclo[2.2.2]octane (RJR-2429): A selective ligand at nicotinic acetylcholine receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 3, 1998, Pages 886-894

  Bencherif, M ^a   Schmitt, J D ^b   Bhatti, B S ^c   Crooks, P ^c   Caldwell, W S ^a   Lovette, M E ^a   Fowler, K ^a   Reeves, L ^a   Lippiello, P M ^a  

^a Pharmacology Division   (United States)

^b UNIVERSITY OF BATH   (United Kingdom)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 PYRIDINYL)QUINUCLIDINE; BICYCLO[2.2.2]OCTANE DERIVATIVE; DOPAMINE; EPIBATIDINE; LIGAND; NICOTINE; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LINE; DOSE RESPONSE; DRUG EFFECT; FEMALE; GUINEA PIG; INTESTINE CONTRACTION; LIGAND BINDING; MALE; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION; SYNAPTOSOME;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; CHOLINERGIC AGENTS; FEMALE; GUINEA PIGS; HUMANS; LIGANDS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NICOTINE; PYRIDINES; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031912620     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Abreo MA, Lin NH and Garvey SD (1996) Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem 39:817-825.
2. Alkondon M, and Albuquerque EX (1993) Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther 265:1455-1473.
3. Alkondon M, Reinhardt S, Lobron C, Hermsen B, Maelicke A and Albuquerque EX (1994) Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist-elicited whole-cell currents and identification of receptors subunits by in situ hybridization. J Pharmacol Exp Ther 271:494-506.
4. Arneric SP, Sullivan JP and Williams M (1995) Neuronal nicotinic acetylcholine receptors-novel targets for CNS therapeutics, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ, eds) pp 1-16, Raven Press, New York.
5. Baron JA (1994) The epidemiology of cigarette smoking and Parkinson'a disease, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS, Quik M, Adlkofer F and Thurau K, eds) pp 313-319, Birkhauser Verlag Basel.
6. Bencherif M, Lovette ME, Fowler KW, Arlington S, Reeves L, Caldwell WS and Lippiello PM (1996) RJR-2403: A nicotinic agonist with CNS selectivity. I. In vitro characterization. J Pharmacol Exp Ther 279:1413-1421.
7. Bencherif M and Lukas RJ (1991a) Differential regulation of nicotinic acetylcholine receptor expression by human TE671/RD cells following second messenger modulation and sodium butyrate treatments. Mol Cell Neurosci 2:52-65.
8. Bencherif M and Lukas RJ (1991b) Ligand binding and functional characterization of muscarinic acetylcholine receptors on the TE671/RD cells. J Pharmacol Exp Ther 257:946-953.
9. Bencherif M and Lukas RJ (1993) Cytochalasin modulation of nicotinic cholinergic receptor expression and muscarinic receptor function in human TE671/RD cells: A possible functional role of the cytoskeleton. J Neurochem 61:852-864.
10. Boulter J, Connolly J, Deneris ES, Goldman D, Heinemann S and Patrick J (1987) Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family. Proc Natl Acad Sci USA 84:7763-7767.
11. Calderon-Gonzalez R (1993) Attention deficit disorders spectrum: Neurological and neuropsychological basis. Internat Pediat 8:176-188.
12. Calkins BM (1989) A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 34:1841-1854.
13. 3H]-dopamine release. Brit J Pharmacol 117:595-606.
14. Cosford NDP, Bleitcher L, Herbaut A, McCallum JS, Vernier JM. Dawson H, Whitten JP, Adams P. Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK and McDonald IA (1996) (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): A novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 39:3235-3237.
15. Couturier S, Bertrand D, Matter J-M, Hernandez M-C, Bertrand S, Millar N, Valera S, Barkas T and Ballivet M (1990) A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron 5:847-856.
16. Davies P and Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
17. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJB, Giardina WJ, Wasicak JT, Garvey DS, Williams M and Arneric SP (1994) (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 270:319-328.
18. 125I-α-bungarotoxin receptor subtypes. Mol Pharmacol 47:164-171.
19. Deneris ES, Connolly JG, Boulter J, Wada E, Wada K, Swanson LW, Patrick J and Heinemann S (1988) Primary structure and expression of beta2: A novel subunit of neuronal nicotinic acetylcholine receptors. Neuron 1:45-54.
20. Deneris ES, Connolly JG, Rogers SW and Duvoisin R (1991) Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci 12:34-40.
21. Devor EJ and Isenberg KE (1989) Nicotine and Tourette's syndrome. Lancet 8670: 1046.
22. Dewar MJS, Zoebisch EG, Healy EF and Stewart JJP (1985) AMI: A new general purpose quantum mechanical molecular model. J Am Chem Soc 107:3902-3909.
23. Elogoyhen AB, Johnson D, Boulter J, Vetter D and Heineman SF (1994) Alpha-9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79:705-715.
24. Emerich DF, Norman AB and Sanberg PR (1991) Nicotine potentiates the behavioral effects of haloperidol. Psychopharmacol Bull 27:385-390.
25. Freedman R, Leonard S, Adler P, Bickford P, Byerley W, Coon H, Miller Luntz-Leybman V, Myles-Worsley M, Nagamoto H, Rose G, Stevens K and Waldo M (1994) Nicotine receptors and the pathophysiology of schizophrenia, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clark PBS, Quik M, Adlkofer F and Thurau K, eds) pp 307-312, Birkhauser Verlag Basel.
26. Galzi J-L, Edelstein SJ and Changeux J-P (1996) The multiple phenotypes of allosteric receptor mutants. Proc Natl Acad Sci 93:1853-1858.
27. Garvey DS, Wasicak J, Decker MW. Brioni JD, Buckley MJ, Sullivan JP, Carrera GM, Holladay MW and Williams M (1994a) Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J Med Chem 37:1055-1059.
28. Garvey DS, Wasicak J, Elliott RL, Lebold SA, Hettinger A-M, Carrera GM, Lin N-H, He Y, Holladay MW, Anderson DJ, Cadman ED, Raszkiewicz JL, Sullivan JP and Arneric SP (1994b) Ligands for brain cholinergic channel receptors: Synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine. J Med Chem 37:4455-4463.
29. Glennon RA, Herndon JL and Dukat M (1994) Epibatidine-aided studies toward definition of nicotine receptor pharmacophore. Med Chem Res 4:461-473.
30. Goldman D, Deneris E, Luyten W, Kochhar A, Patrick J and Heinemann S (1987) Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system. Cell 48:965-973.
31. 3H]-dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 59:848-856.
32. Hughes JR and McHugh P (1994) Nicotine and neuropsychiatric disorders: Schizophrenia, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS, Quik M, Adlkofer F and Thurau K eds) pp 301-305, Birkhauser Verlag Basel.
33. Janson AM, Moller A, Hedlund PB, von Euler G and Fuxe K (1994) Nicotine and animal models of Parkinson's Disease, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS. Quik M, Adlkofer F and Thurau K eds) pp 321-328, Birkhauser Verlag Basel.
34. Jarvik ME (1991) Beneficial effects of nicotine. British J of Addiction 86:571-575.
35. Jones GM, Sahakian BJ, Levy R, Warburton DM and Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing, and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
36. Joseph MH, Grigoryan G, Hodges H and Gray JA (1994) Possible mechanisms underlying beneficial effects of nicotine on cognitive function, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS, Quik M, Adlkofer F and Thurau K eds) pp 337-344, Birkhauser Verlag Basel.
37. Karlin A (1993) Structure of nicotinic acetylcholine receptors. Curr Opin Neurobiol 3:299-309.
38. Levin ED and Torry D (1994) Nicotine effects on memory performance, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS, Quik M, Adlkofer F and Thurau K eds) pp 329-335. Birkhauser Verlag Basel.
39. Lin N-H, Carrera GM and Anderson DJ (1994) Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands. J Med Chem 37: 3542-3553.
40. Lippiello PM, Bencherif M, Gray JA, Peters S, Grigoryan G, Hodges S and Collins AC (1996) RJR-2403: A nicotinic agonist with CNS selectivity. I. In vivo characterization. J Pharmacol Exp Ther 279:1422-1429.
41. 3H]nicotine binding to putative high affinity receptor sites in rat brain. Mol Pharmacol 31:392-400.
42. Luetje CW and Patrick J (1991) Both α- and β-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci 55:837-845.
43. Lukas RJ (1989) Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma. J Pharmacol Exp Ther 251:175-182.
44. Lukas RJ and Bencherif M (1992) Heterogeneity and regulation of nicotinic acetylcholine receptors, Intl Rev Neurobiol 34:25-130.
45. Luther MA, Schoepfer R, Whiting P. Casey B, Blatt Y, Montal MS, Montal M and Lindstrom J (1989) A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J Neurosci 9:1082-1096.
46. Marks MJ, Farnham DA, Grady SR and Collins AC (1993) Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J Pharmacol Exp Ther 264:542-552.
47. McAllister RM, Issacs H, Rongey R, Peer M, Au W, Soukup SW and Gardner MB (1977) Establishment of a human medulloblastoma cell line TE671. J Neurosci 9:1082-1096.
48. McConville BJ, Fogelson HM, Norman AB, Klykylo WM, and Mandersheid PZ (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psych 148:793-794.
49. McConville BJ, Sanberg PR, Fogelsou HM, King J, Cirino P, Parker KW and Norman AB (1992) The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry 31:832-840.
50. Nef P, Oneyser C, Alliod C, Couturier S and Ballivet M (1988) Genes expressed in the brain define three distinct neuronal nicotinic acetylcholine receptors. Embo J 7:595-601.
51. Newhouse PA, Potter A, Piasecki M, Geelmuyden J, Corwin J and Lenox R (1994) Nicotinic modulation of cognitive functioning in humans, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS, Quik M, Adlkofer F and Thurau K eds) pp 345-351, Birkhauser Verlag Basel.
52. Papke RL (1993) The kinetic properties of neuronal nicotinic receptors: Genetic basis of functional diversity. Progr in Neurobiol 41:509-531.
53. Papke RL and Heinemann SF (1994) Partial agonist properties of cytisine on neuronal nicotinic receptors containing the/32 subunits. Mol Pharmacol 45:142-149.
54. Rappe AK, Casweit CJ, Colwell KS, Goddard WA and Skiff WM (1992) UFF: A full periodic table force field for molecular mechanics and molecular dynamics. J Am Chem Soc 114:10024-10029.
55. Rogers SW, Mandelzys A, Deneris ES, Cooper E and Heinemann S (1992) The expression of nicotinic acetylcholine receptor by PC12 cells treated with NGF. J Neurosci 12:4611-4623.
56. Sahakian B, Jones G, Levy R, Gray J and Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psych 154:797-800.
57. Sargent PB (1993) The diversity of neuronal nicotinic acetylcholine receptors. Ann Rev Neurosci 16:403-443.
58. Silver AA, Shytle RD, Philipp MK and Sanberg PR (1994) Transdermal nicotine in Tourette's syndrome, in International Symposium on Nicotine: The effects of nicotine on biological systems. II. Advances in Pharmacological Sciences (Clarke PBS, Quik M, Adlkofer F and Thurau K eds) pp 293-299, Birkhauser Verlag Basel.
59. Smith CP, Brougham LR and Vargas HM (1993) Linopirdine (DuP 996) selectively enhances acetylcholine release induced by high potassium, but not electrical stimulation, in rat brain slices and guinea pig ileum. Drug Develop Res 29:262-270.
60. Smith CJ and Giacobini E (1992) Nicotine, Parkinson's and Alzheimer's disease. Rev Neurosci 3:25-43.
61. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
62. Stewart JPP (1990) MOPAC 6.0. Quantum Chemistry Program Exchange.
63. Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, KangCH, Adams P, Piattoni-Kaplan M, Buckley MJ, Gopalakrishnan M, Williams M and Arneric SP (1994) (+/-) 1-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 271: 624-631.
64. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger AM, Garvey DS, Wasicak JT, Holladay MW, Williams M and Arneric SP (1996) A-85380 [3-(2(S)-azetidinylmethoxy)pyridine]: in vitro pharmacological properties of a novel, high affinity alpha4 beta2 nicotinic acetylcholine receptor ligand. Neuropharmacology 35:725-734.
65. Whiting PJ, Schoepfer R. Lindstrom MJ and Priestley T (1991) Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol Pharmacol 40:463-472.